Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
afimetoran
- Development stage
- Phase 2
- Lead developer
- NewCo
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Afimetoran is a small molecule immunomodulator that acts as a dual antagonist of toll-like receptor 7 (TLR7) and toll-like receptor 8 (TLR8). It is being developed primarily for the treatment of systemic lupus erythematosus (SLE), an autoimmune disease characterized by chronic inflammation and tissue damage. Afimetoran selectively inhibits TLR7 and TLR8 signaling, thereby suppressing downstream inflammatory pathways such as NF-kB and IRF, which are implicated in SLE pathogenesis. Preclinical studies have shown that afimetoran can reduce kidney injury markers, autoantibody titers, and improve steroid response in mouse models of lupus. Clinical trials have demonstrated that afimetoran is safe and well-tolerated in patients with cutaneous lupus erythematosus (CLE) and SLE[1][2][3][4][5][6][7][8]. The drug is currently undergoing phase II clinical evaluation.
- Other names
- afimetoran besilate dihydrate
02
Targets
TLR8 (Toll-like receptor 8)TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on afimetoran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on afimetoran.